一个药理学和脑成像研究人类血管压素AVP1BR受体功能多态
Adrián Alacreu-Crespo1,2, Emilie Olié3,4,5,6, Maxime Manière6
1FondaMental Foundation, Créteil, France. aalacreu@unizar.es.
BMC neuroscience
|July 17, 2025
概括
血管压素V1B受体的遗传变异会影响其功能和大脑活动. 这些人类V1B受体多态可能作为精神疾病的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 血管压素V1B受体 (hV1B) 对于调节下丘脑-垂体-上腺轴和人类的社会行为至关重要.
- 特定的hV1B基因多态 (rs35369693 (K65N),rs28632197 (R364H),rs33990840 (G191R)) 与精神疾病有关,其特征是改变HPA轴功能和社会行为.
研究的目的:
- 在体外研究hV1B受体变异的药理性质.
- 为了检查hV1B多态对人类志愿者的情感识别任务期间大脑活动的影响.
主要方法:
- 对表达不同hV1B变异 (野生型,G191R,K65N,R364H) 的HEK293细胞进行了转染率,光成像和内醇 (IPs) 积累的评估.
- 功能性磁共振成像 (fMRI) 用于在隐性情感识别范式 (愤怒与中立面孔) 中研究35名健康男性的不同hV1B变体的大脑活动.
主要成果:
- 表达hV1B K65N和/或R364H的细胞在氨酸压缩素刺激后显著减少了IPs积累,而G191R变异则增加了它.
- 基础IPs积累,转染率和膜结合在所有测试的多态体中都是一致的.
- 在情感任务期间,K65/R364哈普洛类型的同胞体在运动,视觉,额头,海马和门区域的激活率高于异胞体. 由于低频率,G191的多态性被排除在外.
结论:
- 人类V1B受体多态表现出独特的药理特性,并在情绪处理过程中影响大脑活动.
- 这些hV1B多态体代表精神疾病的潜在生物标志物.
- 考虑到hV1B受体的多形变体,它可能是治疗干预的可行的药理目标.
更多相关视频
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.9K
12:03Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
18.0K
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.9K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.9K
Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Adrenergic Receptors: β Subtype
2.2K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.2K
